SARAH SEELYE: Open Payments
NPI 1750780102 · WACO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$844 in 31 payments from 14 companies in 2025. Trend: 2023 $374 · 2024 $926 · 2025 $844
Food & beverage: $844
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 5 | $164 |
| Dexcom, Inc. | 4 | $147 |
| AstraZeneca Pharmaceuticals LP | 3 | $142 |
| GENZYME CORPORATION | 1 | $88 |
| Sumitomo Pharma America, Inc. | 1 | $49 |
| Astellas Pharma US Inc | 3 | $49 |
| Novo Nordisk Inc | 3 | $47 |
| Organon LLC | 3 | $39 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $35 |
| ABBVIE INC. | 1 | $29 |
Products named: Dexcom G6 Transmitter, ZEPBOUND, AIRSUPRA, DUPIXENT, GEMTESA, JARDIANCE, Veozah, NEXPLANON.
Industry payments across TX — which companies pay providers there.
